Schrödinger announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, an AI co-scientist for molecular discovery, within BMS's research organization.
Bunsen combines artificial intelligence with physics-based simulation to help scientists explore chemical possibilities more systematically, prioritize drug candidates with higher confidence, and accelerate discovery decisions before experimental testing.
What happened
Schrödinger announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, an agentic AI co-scientist designed for molecular discovery, within BMS's research organization. Bunsen executes Schrödinger's physics-based computational methods and works alongside RetroSynth, an AI-driven synthesis planning platform.
Why it matters
BMS scientists will be able to explore more scientific possibilities, prioritize molecules with greater confidence, and accelerate discovery decisions by combining AI with physics-based simulation. The deployment expands Schrödinger's computational platform beyond its established use at BMS and enables a broader group of scientists to adopt a predict-first computational approach to drug discovery.
What to watch
Bunsen is optimized to help researchers understand scientific objectives, plan computational strategies, execute discovery workflows, and interpret results—making advanced computational methods more accessible than before. Interested parties can visit Schrödinger's Bunsen webpage to learn more or sign up for priority access.
Ask the AI about this article →
Schrödinger's agreement with Bristol Myers Squibb represents a major deployment of its agentic AI technology into a large pharmaceutical organization that has already been using Schrödinger's computational platform. BMS, as a long-standing customer and collaborator, has invested in integrating computation into drug discovery over several years. The new Bunsen deployment extends this relationship by enabling scientists to work with AI-assisted molecular discovery workflows at scale. According to Stephen Johnson, Vice President of Computational Sciences at BMS, AI has already become a key enabler for the company's scientists, allowing them to scale their creativity across the research organization; Bunsen is positioned as another capability in that toolkit. The agreement also involves joint development of novel functionality within Bunsen in conjunction with BMS scientists, suggesting that the partnership will evolve over time to meet the pharmaceutical company's specific research needs.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
AI system scaling has pushed interconnect requirements inside data centers from chips and boards up to racks…
Chinese large-model developer Z.ai says it can now support large-scale inference using roughly 100,000 domesti…
Analyst Ming-Chi Kuo says Nvidia has revived the Rubin CPX AI accelerator with a substantially redesigned arch…
Palantir Technologies stock has posted multi-year gains, including an 11x return over 3 years
Apple has escalated its legal battle against OpenAI, claiming in a new court filing that OpenAI is actively de…
Samsung Electronics has locked up as much as 70% of its memory production capacity under long-term supply agre…
